AlphAIAlphAI — Financial news for AI agents
cyprus-mail.comSEP 242 min read

Dentsply Sirona returns to profit, a medical-device win in Armistice Capital’s Healthcare Book

Dentsply Sirona reported a Q2 2026 profit of $37M, reversing a $45M loss from the prior year, despite a 4.1% sales decline to $898M. Gross margin improved to 54.9%, and operating cash flow doubled to $99M. The company's turnaround plan aims for $120M in annual savings. Management maintained its full-year outlook.

Original reporting
cyprus-mail.com
Published Sep 24, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Dentsply Sirona returns to profit, a medical-device win in Armistice Capital’s Healthcare Book — source image
Source · cyprus-mail.com
Decision brief

The 30-second read

Med
01

Why it matters

The earnings beat supports the Return‑to‑Growth Action Plan and could trigger a price rally.

02

Market read

First profit after a loss provides fresh catalyst for DENT and may lift the dental‑device sector.

03

What to watch

Tariff refunds and inventory management drove cash flow; underlying demand softness persists.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release

Background

Dentsply Sirona reported Q2 2026 results, turning a $45M loss into a $37M profit while sales fell modestly.

Market effects

Sector

Dental equipment segment may see renewed investor interest; peers like Align and Envista could benefit from sector momentum.

Regional

U.S. healthcare equipment market gains confidence from Dentsply's turnaround.

Global

Limited to dental‑device niche but signals broader medical‑device recovery trends.

Counterpoint

What could challenge this read

Profit may be temporary if demand for capital‑intensive equipment remains weak.

Key entities

  • company
    Dentsply Sirona

    Dental‑equipment maker, ticker DENT.

  • investment_firm
    Armistice Capital

    Holdings manager highlighting the turnaround.

Read at source← All news

Related articles

SEP 17
Med

Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

Dentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.

investing.com2 min
SEP 3
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

insidermonkey.com3 min
AUG 26
$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

dentistrytoday.com2 min
AUG 14
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

fool.com6 min
AUG 9
$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

yahoo.com6 min
AUG 7
$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

financialcontent.com3 min